{"schema_version":"secwatch.filing_event.v1","accession":"0001690585-26-000033","form_type":"8-K","ticker":"DNTH","cik":"0001690585","company_name":"Dianthus Therapeutics, Inc. /DE/","filed_at":"2026-08-04T20:05:21+00:00","discovered_at":"2026-08-04T20:07:00.223737+00:00","generated_at":"2026-08-04T20:07:10.060057+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Dianthus Q2 net loss $50.2M; CIDP trial 75% response; cash $1.2B","bullets":["Net loss $50.2M ($0.90/share) vs $31.6M ($0.88) in Q2 2025; R&D $48.7M, G&A $13.6M.","Cash $1.2B as of June 30, 2026, providing runway into 2030.","Phase 3 CAPTIVATE (CIDP) interim: 75% response rate in first 40 patients; Part B guidance by YE'26.","Phase 3 EMERGE (gMG) initiated; top-line results expected 2H'28.","Phase 2 MoMeNtum (MMN) enrollment completed (46 patients); top-line Dec '26."],"urls":{"canonical":"https://secwatch.observer/filing/0001690585-26-000033","json":"https://secwatch.observer/filing/0001690585-26-000033.json","markdown":"https://secwatch.observer/filing/0001690585-26-000033.md","text":"https://secwatch.observer/filing/0001690585-26-000033.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1690585/000169058526000033/0001690585-26-000033-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1690585/000169058526000033/dnth-20260804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-04T20:07:10.060057+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}